Stifel analyst Stephen Willey has adjusted his model to a "substantially more-conservative scenario" for the launch of sotagliflozin for Type 1 diabetes following Lexicon's disclosure of its receipt of a Complete Response Letter, or CRL, from the FDA regarding its new drug application. He sees a lack of near-term visibility into what will be needed to satisfy the agency's concerns and now assumes a T1D commercial launch in the first half of 2021, Willey tells investors. He lowered his price target on Lexicon shares to $10 from $14 and admits that the near-term uncertainty "makes it increasingly difficult to stay positive on the stock," but Willey keeps a Buy rating as he sees multiple milestone-yielding data disclosures upcoming from the company's studies in Type 2 diabetes.